PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Combined assessment of serum folate and hemoglobin as biomarkers of brain amyloid β accumulation.

Abstract A relationship between Alzheimer's disease (AD) and folate has been reported. Amyloid positron emission tomography (PET) is currently one of the most reliable biomarkers for AD. We investigated the correlation between serum folate levels and amyloid imaging to clarify whether serum folate could be a biomarker for AD. We also examined the usefulness of a combined assessment of serum folate levels and red blood cell hemoglobin content. Apolipoprotein E (APOE) gene polymorphisms were also assessed. Serum folate levels and hemoglobin content were evaluated by receiver operating characteristic analysis for their diagnostic capability as AD biomarkers relating to brain amyloid β accumulation. The area under the ROC curve (AUC) for serum folate was 0.136 (95% confidence interval [CI]: 0.000-0.312; p = 0.016). The AUC for hemoglobin content was 0.848 (95% CI: 0.661-1.000; p = 0.021). Therefore, the folate deficiency with low folate levels or the non-anaemia with high hemoglobin content levels were found to have a high probability of also testing positive for amyloid. Furthermore, eight patients were found to be folate deficiency and non-anaemia, those who were consist of 7 amyloid positive patients (87.5%), and only one of the amyloid negative patients (12.5%). These results suggest that a deficiency of serum folate and high hemoglobin levels may reflect an increased risk of amyloid β accumulation in the brain. Additionally, we demonstrated that these biomarkers could enhance the effectiveness of APOE as an AD biomarker. This study reveals that the combined assessment of serum folate levels and red blood cell hemoglobin content may be a useful biomarker for amyloid β accumulation in the brain. We also found that the combination of serum folate levels and hemoglobin content is a more specific and sensitive blood biomarker for AD than APOE or folate alone. These findings may be used to support clinical diagnosis of AD using a simple blood test.
PMID
Related Publications

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with 18Fflorbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 28406978
OWN - NLM
STAT- MEDLINE
DA  - 20170413
DCOM- 20170420
LR  - 20170420
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Combined assessment of serum folate and hemoglobin as biomarkers of brain amyloid
      beta accumulation.
PG  - e0175854
LID - 10.1371/journal.pone.0175854 [doi]
AB  - A relationship between Alzheimer's disease (AD) and folate has been reported.
      Amyloid positron emission tomography (PET) is currently one of the most reliable 
      biomarkers for AD. We investigated the correlation between serum folate levels
      and amyloid imaging to clarify whether serum folate could be a biomarker for AD. 
      We also examined the usefulness of a combined assessment of serum folate levels
      and red blood cell hemoglobin content. Apolipoprotein E (APOE) gene polymorphisms
      were also assessed. Serum folate levels and hemoglobin content were evaluated by 
      receiver operating characteristic analysis for their diagnostic capability as AD 
      biomarkers relating to brain amyloid beta accumulation. The area under the ROC
      curve (AUC) for serum folate was 0.136 (95% confidence interval [CI]:
      0.000-0.312; p = 0.016). The AUC for hemoglobin content was 0.848 (95% CI:
      0.661-1.000; p = 0.021). Therefore, the folate deficiency with low folate levels 
      or the non-anaemia with high hemoglobin content levels were found to have a high 
      probability of also testing positive for amyloid. Furthermore, eight patients
      were found to be folate deficiency and non-anaemia, those who were consist of 7
      amyloid positive patients (87.5%), and only one of the amyloid negative patients 
      (12.5%). These results suggest that a deficiency of serum folate and high
      hemoglobin levels may reflect an increased risk of amyloid beta accumulation in
      the brain. Additionally, we demonstrated that these biomarkers could enhance the 
      effectiveness of APOE as an AD biomarker. This study reveals that the combined
      assessment of serum folate levels and red blood cell hemoglobin content may be a 
      useful biomarker for amyloid beta accumulation in the brain. We also found that
      the combination of serum folate levels and hemoglobin content is a more specific 
      and sensitive blood biomarker for AD than APOE or folate alone. These findings
      may be used to support clinical diagnosis of AD using a simple blood test.
FAU - Yoshinaga, Takuma
AU  - Yoshinaga T
AUID- ORCID: http://orcid.org/0000-0001-9897-6113
AD  - Division of Clinical Application, Nanpuh Hospital, Kagoshima, Japan.
FAU - Nishimata, Hiroto
AU  - Nishimata H
AD  - Gastroenterology, Nanpuh Hospital, Kagoshima, Japan.
FAU - Kajiya, Yoriko
AU  - Kajiya Y
AD  - Radiology, Nanpuh Hospital, Kagoshima, Japan.
FAU - Yokoyama, Shunichi
AU  - Yokoyama S
AD  - Neurosurgery, Nanpuh Hospital, Kagoshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170413
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Biomarkers)
RN  - 0 (Hemoglobins)
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*diagnosis/metabolism
MH  - Amyloid beta-Peptides/*metabolism
MH  - Apolipoproteins E/genetics
MH  - Biomarkers/metabolism
MH  - Brain/*metabolism
MH  - Female
MH  - Folic Acid/*blood
MH  - Hemoglobins/*metabolism
MH  - Humans
MH  - Male
MH  - Polymorphism, Single Nucleotide
MH  - Positron-Emission Tomography/methods
EDAT- 2017/04/14 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/04/14 06:00
PHST- 2016/12/06 [received]
PHST- 2017/03/31 [accepted]
AID - 10.1371/journal.pone.0175854 [doi]
AID - PONE-D-16-48301 [pii]
PST - epublish
SO  - PLoS One. 2017 Apr 13;12(4):e0175854. doi: 10.1371/journal.pone.0175854.
      eCollection 2017.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>